PROPEL: A randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients

Hepatology

Volumn 58, Issue 2, 2013, Pages 524-537

  Wedemeyer, Heiner ^a   Jensen, Donald ^b   Herring, Robert ^c   Ferenci, Peter ^d   Ma, Mang Ming ^e   Zeuzem, Stefan ^f   Rodriguez Torres, Maribel ^g   Bzowej, Natalie ^h   Pockros, Paul ⁱ   Vierling, John ^j   Ipe, David ^k   Munson, Marie Lou ^k   Chen, Ya Chi ^l   Najera, Isabel ^l   Thommes, James ^k  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c Nashville Gastrointestinal Specialists Inc   (United States)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF ALBERTA   (Canada)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g Fundacion de Investigacion de Diego   (Puerto Rico)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

^j CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^k GENENTECH INC   (United States)

^l HOFFMANN LA ROCHE INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B; MERICITABINE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ALOPECIA; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ASTHENIA; CHILL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; EVENING DOSAGE; FATIGUE; FEMALE; FOLLOW UP; GENOTYPE; HAND RASH; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INSOMNIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NUCLEOTIDE SEQUENCE; PHASE 2 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN PRURITUS; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS INHIBITION;

ADOLESCENT; ADULT; AGED; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84879211393     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26274     Document Type: Article

References (19)

1. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-1374.
2. European Association for the Study of the Liver et al. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011;55:245-264.
3. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011;54:1433-1444.
4. Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-1206.
5. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1207-1217.
6. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-2416.
7. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011;365:1014-1024.
8. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-2428.
9. Sarrazin C, Hezode C, Zeuzem S, Pawlotsky JM. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012;56(Suppl 1):S88-S100.
10. Stuyver LJ, McBrayer TR, Tharnish PM, Clark J, Hollecker L, Lostia S, et al. Inhibition of hepatitis C replicon RNA synthesis by beta-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine: a specific inhibitor of hepatitis C virus replication. Antivir Chem Chemother 2006;17:79-87.
11. Wang M, Ng KK, Cherney MM, Chan L, Yannopoulos CG, Bedard J, et al. Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. J Biol Chem 2003;278:9489-9495.
12. Guedj J, Dahari H, Shudo E, Smith P, Perelson AS. Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128). Hepatology 2012;55:1030-1037.
13. Ma H, Jiang WR, Robledo N, Leveque V, Ali S, Lara-Jaime T, et al. Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2′-deoxy-2′-fluoro-2′-C-methylcytidine (PSI-6130) and identification of a novel active 5′-triphosphate species. J Biol Chem 2007;282:29812-29820.
14. Murakami E, Tolstykh T, Bao H, Niu C, Steuer HM, Bao D, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem 2010;285:34337-34347.
15. Kowdley K, Lawitz E, Crespo I, Hassanein T, Davis M, DeMicco M, et al. GS-7977 + PEG/RBC in HCV genotype 1: the Atomic trial an end to response-guided therapy? Oral presentation at the International Liver Congress 2012 (47th Annual Meeting of the European Association for the Study of the Liver [EASL]), April 18-22, 2012, Barcelona, Spain.
16. Pockros PJ, Jensen D, Tsai N, Taylor R, Ramji A, Cooper C, et al. JUMP-C: A randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin for 24 weeks in treatment-naïve HCV genotype 1/4 patients. Hepatology 2013; doi: 10.1002/hep.26275.
17. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-2416.
18. Incivek prescribing information. Revised June 2012. Vertex Pharmaceuticals Inc., Cambridge, MA.
19. Victrelis prescribing information. Revised July 2012. Merck and Co., Whitehouse Station, NJ.